HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial

导出原文传递

翻译打印收藏纠错

作者： Llombart-Cussac, Antonio ^[1] ; Cortes, Javier ^[2] ; Pare, Laia ^[3] ; Galvan, Patricia ^[4] ; Bermejo, Begona ^[5] ; Martinez, Noelia ^[6] ; Vidal, Maria ^[7] ; Pernas, Sonia ^[8] ; Lopez, Rafael ^[9] ; Munoz, Montserrat ^[10] ; Nuciforo, Paolo ^[11] ; Morales, Serafin ; Oliveira, Mafalda ; de la Pena, Lorena ; Pelaez, Alexandra ; Prat, Aleix

作者单位： Complejo Univ Santiago Compostela, Santiago De Compostela, Spain ^[1] Hosp Univ Ramon y Cajal, Madrid, Spain ^[2] VHIO, Barcelona, Spain ^[3] Hosp Univ Vall Hebron, Barcelona, Spain ^[4] Hosp Arnau Vilanova, Valencia, Spain ^[5] SOLTI Breast Canc Res Grp, Barcelona, Spain ^[6] Hosp Clin Valencia, Valencia, Spain ^[7] Inst Catalan Oncol, Barcelona, Spain ^[8] Hosp Clin Barcelona, Barcelona, Spain ^[9] Hosp Arnau Vilanova, Lleida, Spain ^[10] VHIO, Mol Oncol Lab, Barcelona, Spain ^[11]

发布时间 2018-09-20

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览2

The lancet oncology

2017年18卷4期

545-554页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial

The lancet oncology

相似文献

The lancet oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial

The lancet oncology

相似文献

The lancet oncology

相关期刊

检索历史清除